Clinical trial

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention FF/UMEC/VI Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Tiotropium Normalized identity: tiotropium View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Albuterol/salbutamol Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo to match FF/UMEC/VI Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo to match tiotropium Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention ELLIPTA inhaler Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention HANDIHALER Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention MDI Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-03-29

PhasePHASE4

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

FF/UMEC/VIDRUG

TiotropiumDRUG · verified · RxNorm: tiotropium

Albuterol/salbutamolDRUG

Placebo to match FF/UMEC/VIDRUG

Placebo to match tiotropiumDRUG

ELLIPTA inhalerDEVICE

HANDIHALERDEVICE

MDIDEVICE

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Parexelcollaborator

Mapped research locations

Saint PetersburgRussia4 MoscowRussia3 MiamiFlorida, United States2 KrakowPoland2 BialystokPoland2 BydgoszczPoland2 NovosibirskRussia2 CincinnatiOhio, United States1 MinneapolisMinnesota, United States1 OrlandoFlorida, United States1 Salt Lake CityUtah, United States1 WarsawPoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03474081 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.